Actively Recruiting
CAR T-cell Therapy in Patients With Renal Dysfunction
Led by Northside Hospital, Inc. · Updated on 2026-04-20
20
Participants Needed
1
Research Sites
145 weeks
Total Duration
On this page
Sponsors
N
Northside Hospital, Inc.
Lead Sponsor
B
Blood and Marrow Transplant Group of Georgia
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
CONDITIONS
Official Title
CAR T-cell Therapy in Patients With Renal Dysfunction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
- Adequate bone marrow function to receive lymphodepleting chemotherapy
- Renal function </= 60mL/min/1.73m2
- ECOG 0-2
You will not qualify if you...
- Relative CNS disorders
- Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
- Use of therapeutic dose systemic corticosteroids (defined as >20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Caitlin Guzowski
Atlanta, Georgia, United States, 30342
Actively Recruiting
Research Team
M
Melhem Solh, MD
CONTACT
C
Caitlin Guzowski, MBA, MHA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here